Most active Reg A+ offerings on Manhattan Street Capital
GolfSuites 1
Investors in GolfSuites 1 receive an 8% per annum dividend (see the Offering Circular for the details), paid monthly from the date of completing their investment with the potential for appreciation in Preferred share price over time.
GolfSuites is a new investment opportunity focused on bringing hybrid-golf centers for year-round play, entertainment and game improvement, to millions of people, in an engaging and friendly environment.
GolfSuites 1 Reg A+ offering is live and accepting investments from investors of all wealth levels. Minimum $500.
View their Offering Circular HERE.
InSitu Biologics
InSitu Biologics is an emerging biotech company focusing on the development of AnestaGel™, a long-acting non-opiate painkiller. Their Pre-clinical studies are completed and now they are preparing the FDA package for Phase 1 Clinical Study. The company has re-opened its Reg A+ after expanding its business by entering the Veterinary Care market with its new AniGel™ product and conducting a two for one share split (meaning that each prior investor via this Reg A+ now owns two shares for every share they initially bought).
Phase 1 Clinical Study manufacturing process development underway. 100 million Americans suffer from chronic pain and on average, 115 Americans die every day from an opioid overdose. InSitu is focused on providing a solution to these problems.
InSitu has already raised more than $3 million, their Reg A+ offering is live and accepting investments from investors of all wealth levels. Minimum $320.
View their Offering Circular HERE.
Note that Manhattan Street Capital receives payments from companies that raise capital on our website. See the Manhattan Street Capital terms